MuratVeyselKalayogluMDPhD, MBA

Physician

Dr. Kalayoglu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Engineered cell therapies for cancer and autoimmune, respiratory and inflammatory diseases

Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2001 - 2004
University of Wisconsin School of Medicine & Public HealthClass of 2000

PubMed

47 citations
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-rand...
Volkan Granit, Michael Benatar, Metin Kurtoglu, Miloš D Miljković, Nizar Chahin
The Lancet. Neurology. 2023-07-01
4 citations
Infection, inflammation and age-related macular degeneration.
Murat V. Kalayoglu, Joan W. Miller
Clinical & Experimental Ophthalmology. 2007-01-01
64 citations
Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration
Murat V. Kalayoglu, Deisy V. Bula, Jorge G. Arroyo, Evangelos S. Gragoudas, Donald J. D'Amico
Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2005-05-21

Dr. Murat Kalayoglu, President & CEO, Cartesian Therapeutics: The Leader in RNA Cell TherapyMay 31st, 2022
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple MyelomaJanuary 25th, 2022
Cartesian Therapeutics Strengthens Leadership Team with Hire of Miloš Miljković, M.D., as Chief Medical OfficerSeptember 28th, 2021
Join now to see all